How to select among available options for the treatment of multiple myeloma

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Harousseau, J L ^a  

^a CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

Autologous stem cell transplantation; Bortezomib; Lenalidomide; Multiple myeloma; Thalidomide

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; MELPHALAN; PLACEBO; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ACUTE LEUKEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CONSOLIDATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FATIGUE; GENETIC DISORDER; HIGH RISK PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MAINTENANCE CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84866745286     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds311     Document Type: Article

References (50)

1. Kumar SK, Rajkumar SV, Dispenzieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
2. Mateos MV, Hernandez T, de la Rubia J et al. Multicenter, randomized, openlabel, phase III trial of lenalidomide-dexamethasone vs therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic MM: results of the first interim analysis. Blood 2009; 114(22): Abstract 614.
3. Harousseau J-L, Moreau P. Autologous stem-cell transplantation in multiple myeloma. N Engl J Med 2009; 360: 2645-2654.
4. Harousseau J-L, Attal M, Avet-Loiseau H. The role of complete remission in multiple myeloma. Blood 2009; 114: 3139-3146.
5. Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma and the impact of novel agents. J Clin Oncol 2010; 28: 2612-2624.
6. Cavo M, Zamagni E, Tosi P et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicine-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35-39.
7. Harousseau J-L, Attal M, Avet-Loiseau H et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010; 28: 4621-4629.
8. Lokhorst HM, Schidt-Wolf I, Sonneveld P et al. Thalidomide in induction treatment increases the very good partial remission rate before and after highdose therapy in previously untreated multiple myeloma. Haematologica 2008; 93: 124-127.
9. Morgan GJ, Davies FE, Gregory WM et al. Cyclophosphamide, thalidomide and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC IX randomized trial results. Haematologica 2012; 97: 442-450.
10. Sonneveld P, van der Holt B, Schmidt-Wolf IGH et al. First analysis of Hovon 65/ GMMG-HD4 randomized Phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction prior to high dose melphalan in patients with newly diagnosed multiple myeloma. Haematologica 2009; 94: Abstract 473.
11. Cavo M, Tacchetti P, Patriarca F et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction before and consolidation therapy after double autologous stem-cell transplantation in newly diagnosed multiple myeloma:a randomized phase 3 study. Lancet 2010; 376: 2075-2085.
12. Moreau P, Avet Loiseau H, Facon T et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatmenet before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011; 118: 5752-5758.
13. Rosinol L, Cibeira T, Martinez J et al. Thalidomide/dexamethasone (TD) versus bortezomib (Velcade)/thalidomide/dexamethasone (VTD) versus VBMCP/VBAD Velcade as induction regimen prior to autologous stem-cell transplantation in multiple myeloma. Results of a phase III Pethema/Gemm trial. Blood 2009; 114: 58-59, Abstract 129.
14. Cavo M, Rajkumar SV, Palumbo A et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2001; 117: 6863-6873.
15. Roussel M, Moreau P, Huinh A et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem-cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010; 115: 32-37.
16. Mellqvist UH, Westin J, Gimsing P et al. Improved response rate with bortezomib consolidation after high-dose melphalan: first results of a Nordic Myeloma Study group randomized Phase III trial. Blood 2009; 114(22): Abstract 530.
17. Ladetto M, Pagliano G, Ferrero S et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010; 28: 2077-2084.
18. Roussel M, Robillard N, Moreau P et al. Bortezomib, lenalidomide and dexamethasone (VRD) consolidation and lenalidomide maintenance in multiple myeloma patients: updated results of the IFM 2008 Phase II VRD intensive program. Blood 2011; 118: Abstract 1872.
19. Attal M, Harousseau JL, Leyvraz S et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 2006; 15: 3289-3294.
20. Barlogie B, Tricot G, Anaissie E et al. Thalidomide and hematopoietic stem cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-1030.
21. Spencer A, Prince HM, Roberts A et al. Consolidation therapy with thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single ASCT procedure. J Clin Oncol 2009; 27: 1788-1793.
22. Lokhorst HM, van der Holt B. Zweegman late. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and highdose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010; 115: 113-120.
23. Morgan GJ, Gregory WM, Davies FE et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC IX results and meta-analysis. Blood 2012; 119: 7-15.
24. Barlogie B, Pineda-Roman M, van Rhee F et al. Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with interphase cytogenetic abnormalities. Blood 2008; 112: 2999-3000.
25. Mac Carthy PL, Owzar K, Hofmeister CC et al. A phase III study of lenalidomide after transplant for multiple myeloma. N Engl J Med 2012; 366: 1770-1781.
26. Palumbo A, Gay F, Falco P et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol 2010; 28: 800-807.
27. Attal M, Cances Lauwers V, Marit G et al. Maintenance treatment with lenalidomide after transplantation for myeloma. N Engl J Med 2012; 366: 1782-1791.
28. Pineda Roman M, Zangari M, Haessler J et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol 2008; 140: 625-634.
29. Shaughnessy JD, Zhou Y, Haessler J et al. TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. Br J Haematol 2009; 147: 347-351.
30. Neben K, Lokhorst HM, Jauch A et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012; 119: 940-948.
31. Rajkumar SV, Jacobus S, Callander NS et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomized controlled trial. Lancet Oncol 2010; 11: 29-37.
32. Niesvizky R, Jayabalan DS, Christos PJ et al. BiRD (Biaxin/Revlimid/ Dexamethasone) combination therapy results in high complete and overall response rates in treatment-naïve symptomatic multiple myeloma. Blood 2008; 111: 1101-1109.
33. Richardson PG, Weller E, Lonial S et al. Lenalidomide, bortezomib and dexamethasone combination therapy in newly diagnosed multiple myeloma. Blood 2010; 116: 679-686.
34. Palumbo A, Bringhen S, Liberati AM et al. Oral melphalan, prednbisone and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008; 112: 3107-3114.
35. Facon T, Mary JY, Hulin C et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 307: 1209-1218.
36. Hulin C, Facon T, Rodon P et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma; IFM 01/01 trial. J Clin Oncol 2009; 27: 3664-3670.
37. Wijermans P, Schaafsma M, Termorhuizen F et al. Phase III study of the value of thalidomide added to melphalan prednisone in elderly patients with newly diagnosed multiple myeloma: the Hovon 49 study. J Clin Oncol 2010; 28: 3160-3166.
38. Waage A, Gimsing P, Fayers P et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 2011; 116: 1405-1411.
39. Beksac M, Haznedar R, Firatli-Tuglular T et al. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a trial from the Turkish Myeloma Study group. Eur J Haematol 2011; 86: 16-22.
40. Fayers PM, Palumbo A, Hulin C et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized trials. Blood 2011; 118: 1239-1247.
41. San Miguel JF, Schlag R, Khuageva NK et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 35: 906-917.
42. Mateos MV, Richardson PG, Schlag R et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the Phase III Vista trial. J Clin Oncol 2010; 28: 2258-2266.
43. Ludwig H, Hajek R, Tothova E et al. Thalidomide-dexamethasone compared to melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2008; 113: 3435-3442.
44. Palumbo A, Hajek R, Delforge M et al. Continuous lenalidomide treatment for newly diagnosed myeloma. N Engl J Med 2012; 366: 1759-1769.
45. Palumbo A, Bringhen S, Rossi D et al. Bortezomib-melphalan-prednisonethalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010; 28: 5101-5109.
46. Mateos MV, Oriol A, Martinez-Lopez J et al. Bortezomib, melphalan and prednisone versus bortezomib, thalidomide and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma; a randomized trial. Lancet Oncol 2010; 11: 934-941.
47. Bringhen S, Larocca A, Rossi D et al. Efficacy and safety of once weekly bortezomib in multiple myeloma patients. Blood 2010; 116: 4745-4753.
48. Palumbo A, Bringhen S, Ludwig H et al. Personalized therapy in multiple myeloma according to patient age and vulnerability. Blood 2011; 118: 4519-4529.
49. Dimopoulos MA, Terpos E, Chanan-Khan A et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of International Myeloma Working Group. J Clin Oncol 2010; 28: 4976-4984.
50. Ludwig H, Adam Z, Hajek R et al. Light chain-induced acute renal failure can be reversed by bortezomib, doxorubicin and dexamethasone in patients with multiple myeloma: results of a phase II study. J Clin Oncol 2010; 28: 4635-4641.